Southwest Airlines (LUV)
(Real Time Quote from BATS)
$30.00 USD
-0.07 (-0.23%)
Updated Jun 5, 2023 03:12 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
LUV 30.00 -0.07(-0.23%)
Will LUV be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LUV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LUV
Airline Stock Roundup: AAL's Bullish Q2 Forecast, ALGT's Labor Deal & More
JETS ETF to Gain on Lower Energy Costs, Consumer Resilience
LUV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Airline Stock Roundup: AZUL Posts Wider Q1 Loss, LUV & ALGT in focus
Southwest Airlines (LUV) Sees Air Travel Demand, Cost Woes Stay
Southwest Airlines (LUV) Pilots Vote in Favor of Strike
Other News for LUV
Airlines Could Fly High This Year
Global airline industry profits are strengthening despite economic turbulence
Goldman Sachs Reaffirms Their Hold Rating on Southwest Airlines (LUV)
Airline Stock Roundup: American Airlines' Bullish Q2 Forecast, Allegiant's Labor Deal & More
JOLT HEALTH INC. ANNOUNCES NEW CEO AND DIRECTOR TO LEAD BIOTECHNOLOGY, HEALTHCARE AND AI INITIATIVES